SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
49,250
+700 (1.44%)
Jan 22, 2026, 3:30 PM KST
-2.67%
Market Cap3.81T
Revenue (ttm)624.03B
Net Income (ttm)-5.90B
Shares Out78.43M
EPS (ttm)-75.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume180,735
Average Volume143,544
Open48,550
Previous Close48,550
Day's Range48,500 - 49,750
52-Week Range35,800 - 61,300
Beta1.12
RSI48.65
Earnings DateJan 29, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 917
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

Financial Statements